Cognitive impairment in Parkinson’s disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health

npj Parkinson's Disease

Volumn 4, Issue 1, 2018, Pages

  Goldman, Jennifer G ^a   Vernaleo, Beth A ^b   Camicioli, Richard ^c   Dahodwala, Nabila ^d   Dobkin, Roseanne D ^e   Ellis, Terry ^f   Galvin, James E ^g   Marras, Connie ^h   Edwards, Jerri ⁱ   Fields, Julie ^j   Golden, Robyn ^a   Karlawish, Jason ^d   Levin, Bonnie ^k   Shulman, Lisa ^l   Smith, Glenn ^m   Tangney, Christine ^a   Thomas, Cathi A ⁿ   Tröster, Alexander I ^o   Uc, Ergun Y ^p   Coyan, Noreen ^q   Ellman, Crystal ^q   Ellman, Mike ^q   Hoffman, Charlie ^q   Hoffman, Susan ^q   Simmonds, Don ^q   more..

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b Parkinson's Disease Foundation   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e RUTGERS UNIVERSITY   (United States)

^f BOSTON UNIVERSITY   (United States)

^g FLORIDA ATLANTIC UNIVERSITY   (United States)

^h TORONTO WESTERN HOSPITAL   (Canada)

ⁱ UNIVERSITY OF SOUTH FLORIDA   (United States)

^j MAYO CLINIC   (United States)

^k UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF FLORIDA   (United States)

ⁿ BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o BARROW NEUROLOGICAL INSTITUTE   (United States)

^p UNIVERSITY OF IOWA   (United States)

^q NONE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN;

AGING; ALZHEIMER DISEASE; ANXIETY; CAREGIVER; CEREBROVASCULAR DISEASE; COGNITION; COGNITIVE DEFECT; COGNITIVE RESERVE; DEMENTIA; DEPRESSION; EXECUTIVE FUNCTION; EXERCISE; HALLUCINATION; HEALTH CARE PERSONNEL; HUMAN; LEWY BODY; LIFESTYLE INTERVENTIONS AND INDEPENDENCE FOR ELDERS; MILD COGNITIVE IMPAIRMENT; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SPATIAL MEMORY TEST; SYMPOSIUM;

EID: 85058860588     PISSN: None     EISSN: 23738057     Source Type: Journal    
DOI: 10.1038/s41531-018-0055-3     Document Type: Review

References (122)

1. Goldman, J. G., Williams-Gray, C., Barker, R. A., Duda, J. E. & Galvin, J. E. The spectrum of cognitive impairment in Lewy body diseases. Mov. Disord. 29, 608–621 (2014).
2. Broeders, M. et al. Cognitive change in newly-diagnosed patients with Parkinson’s disease: a 5-year follow-up study. J. Int. Neuropsychol. Soc. 19, 695–708 (2013).
3. Hoogland, J. et al. Mild cognitive impairment as a risk factor for Parkinson’s disease dementia. Mov. Disord. 10.1002/mds.27002, (2017).
4. Lawson, R. A. et al. Stability of mild cognitive impairment in newly diagnosed Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 88, 648–652 (2017).
5. Pedersen, K. F., Larsen, J. P., Tysnes, O. B. & Alves, G. Natural course of mild cognitive impairment in Parkinson disease: a 5-year population-based study. Neurology 88, 767–774 (2017).
6. Hely, M. A., Reid, W. G., Adena, M. A., Halliday, G. M. & Morris, J. G. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov. Disord. 23, 837–844 (2008).
7. Emre, M. et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov. Disord. 22, 1689–1707 (2007).
8. Williams-Gray, C. H., Foltynie, T., Brayne, C. E., Robbins, T. W. & Barker, R. A. Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain 130, 1787–1798 (2007).
9. Aarsland, D. et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 75, 1062–1069 (2010).
10. Irwin, D. J. et al. Neuropathologic substrates of Parkinson disease dementia. Ann. Neurol. 72, 587–598 (2012).
11. Williams-Gray, C. H. et al. The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN Cohort. Brain 132, 2958–2969 (2009).
12. Kehagia, A. A., Barker, R. A. & Robbins, T. W. Cognitive impairment in Parkinson’s disease: the dual syndrome hypothesis. Neurodegener. Dis. 11, 79–92 (2013).
13. Halliday, G. M., Leverenz, J. B., Schneider, J. S. & Adler, C. H. The neurobiological basis of cognitive impairment in Parkinson’s disease. Mov. Disord. 29, 634–650 (2014).
14. Grahn, J. A., Parkinson, J. A. & Owen, A. M. The cognitive functions of the caudate nucleus. Progr Neurobiol. 86, 141–155 (2008).
15. Hepp, D. H. et al. Distribution and load of amyloid-beta pathology in Parkinson disease and dementia with Lewy bodies. J. Neuropathol. Exp. Neurol. 75, 936–945 (2016).
16. Johar, I., Mollenhauer, B. & Aarsland, D. Cerebrospinal fluid biomarkers of cognitive decline in Parkinson’s disease. Int Rev. Neurobiol. 132, 275–294 (2017).
17. Compta, Y. et al. Lewy- and Alzheimer-type pathologies in Parkinson’s disease dementia: which is more important? Brain 134, 1493–1505 (2011).
18. Petrou, M., Kotagal, V. & Bohnen, N. I. An update on brain imaging in parkinsonian dementia. Imaging Med. 4, 201–213 (2012).
19. Vesely, B. & Rektor, I. The contribution of white matter lesions (WML) to Parkinson’s disease cognitive impairment symptoms: a critical review of the literature. Park. Relat. Disord. 22(Suppl. 1), S166–S170 (2016).
20. Christopher, L. et al. Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson’s disease with mild cognitive impairment. Brain 137, 565–575 (2014).
21. Litvan, I. et al. MDS Task Force on mild cognitive impairment in Parkinson’s disease: critical review of PD-MCI. Mov. Disord. 26, 1814–1824 (2011).
22. Jozwiak, N. et al. REM sleep behavior disorder and cognitive impairment in Parkinson’s disease. Sleep 40, 10.1093/sleep/zsx101, (2017).
23. Vendette, M. et al. REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia. Neurology 69, 1843–1849 (2007).
24. Goldman, J. G. et al. Dissociations among daytime sleepiness, nighttime sleep, and cognitive status in Parkinson’s disease. Park. Relat. Disord. 19, 806–811 (2013).
25. Goldman, J. G., Stebbins, G. T., Leung, V., Tilley, B. C. & Goetz, C. G. Relationships among cognitive impairment, sleep, and fatigue in Parkinson’s disease using the MDS-UPDRS. Park. Relat. Disord. 20, 1135–1139 (2014).
26. Mata, I. F. et al. APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. JAMA Neurol. 71, 1405–1412 (2014).
27. Morley, J. F. et al. Genetic influences on cognitive decline in Parkinson’s disease. Mov. Disord. 27, 512–518 (2012).
28. Goris, A. et al. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson’s disease. Ann. Neurol. 62, 145–153 (2007).
29. Seto-Salvia, N. et al. Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes. Arch. Neurol. 68, 359–364 (2011).
30. Huang, X., Chen, P., Kaufer, D. I., Troster, A. I. & Poole, C. Apolipoprotein E and dementia in Parkinson disease: a meta-analysis. Arch. Neurol. 63, 189–193 (2006).
31. Williams-Gray, C. H. et al. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson’s disease. J. Neurol. 256, 493–498 (2009).
32. Guerini, F. R. et al. BDNF Val66Met polymorphism is associated with cognitive impairment in Italian patients with Parkinson’s disease. Eur. J. Neurol. 16, 1240–1245 (2009).
33. Gao, L. et al. Brain-derived neurotrophic factor G196A polymorphism and clinical features in Parkinson’s disease. Acta Neurol. Scand. 122, 41–45 (2010).
34. Wang, M., Norman, J. E., Srinivasan, V. J. & Rutledge, J. C. Metabolic, inflammatory, and microvascular determinants of white matter disease and cognitive decline. Am. J. Neurodegener. Dis. 5, 171–177 (2016).
35. Gorelick, P. B. et al. Defining optimal brain health in adults: a presidential advisory from the American Heart Association/American Stroke Association. Stroke 48, e284–e303 (2017).
36. Vauzour, D. et al. Nutrition for the ageing brain: towards evidence for an optimal diet. Ageing Res Rev. 35, 222–240 (2017).
37. Smith, E., Hay, P., Campbell, L. & Trollor, J. N. A review of the association between obesity and cognitive function across the lifespan: implications for novel approaches to prevention and treatment. Obes. Rev. 12, 740–755 (2011).
38. van den Berg, E., Kloppenborg, R. P., Kessels, R. P., Kappelle, L. J. & Biessels, G. J. Type 2 diabetes mellitus, hypertension, dyslipidemia and obesity: a systematic comparison of their impact on cognition. Biochim. Et. Biophys. Acta 1792, 470–481 (2009).
39. Delgado-Alvarado, M., Gago, B., Navalpotro-Gomez, I., Jimenez-Urbieta, H. & Rodriguez-Oroz, M. C. Biomarkers for dementia and mild cognitive impairment in Parkinson’s disease. Mov. Disord. 31, 861–881 (2016).
40. Khan, A. A., Quinn, T. J., Hewitt, J., Fan, Y. & Dawson, J. Serum uric acid level and association with cognitive impairment and dementia: systematic review and meta-analysis. Age 38, 16 (2016).
41. Mielke, M. M. et al. Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson’s disease and associated with cognitive impairment: a pilot study. PLoS ONE 8, e73094 (2013).
42. Graham, J. E. et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet 349, 1793–1796 (1997).
43. Knopman, D. S. et al. Brain injury biomarkers are not dependent on beta-amyloid in normal elderly. Ann. Neurol. 73, 472–480 (2013).
44. Petersen, R. C. Mild cognitive impairment. Continuum 22, 404–418 (2016).
45. Litvan, I. et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov. Disord. 27, 349–356 (2012).
46. Galtier, I., Nieto, A., Lorenzo, J. N. & Barroso, J. Mild cognitive impairment in Parkinson’s disease: diagnosis and progression to dementia. J. Clin. Exp. Neuropsychol. 38, 40–50 (2016).
47. Greenaway, M. C., Smith, G. E., Tangalos, E. G., Geda, Y. E. & Ivnik, R. J. Mayo older americans normative studies: factor analysis of an expanded neuropsychological battery. Clin. Neuropsychol. 23, 7–20 (2009).
48. Smith, G. E., Ivnik, R. J. & Lucas, J. A. Assessment Techniques: Tests, Test Batteries, Norms and Methodological Approaches (Taylor & Francis, New York, 2008).
49. Escandon, A., Al-Hammadi, N. & Galvin, J. E. Effect of cognitive fluctuation on neuropsychological performance in aging and dementia. Neurology 74, 210–217 (2010).
50. Marras, C. et al. Measuring mild cognitive impairment in patients with Parkinson’s disease. Mov. Disord. 28, 626–633 (2013).
51. Marras, C., Troster, A. I., Kulisevsky, J. & Stebbins, G. T. The tools of the trade: a state of the art “How to Assess Cognition” in the patient with Parkinson’s disease. Mov. Disord. 29, 584–596 (2014).
52. Chou, K. L. et al. A recommended scale for cognitive screening in clinical trials of Parkinson’s disease. Mov. Disord. 25, 2501–2507 (2010).
53. Kulisevsky, J. & Pagonabarraga, J. Cognitive impairment in Parkinson’s disease: tools for diagnosis and assessment. Mov. Disord. 24, 1103–1110 (2009).
54. Dubois, B. et al. Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov. Disord. 22, 2314–2324 (2007).
55. Martin, R. C. et al. Impaired financial abilities in Parkinson’s disease patients with mild cognitive impairment and dementia. Park. Relat. Disord. 19, 986–990 (2013).
56. Pirogovsky, E. et al. Predictors of performance-based measures of instrumental activities of daily living in nondemented patients with Parkinson’s disease. J. Clin. Exp. Neuropsychol. 35, 926–933 (2013).
57. Brennan, L. et al. The Penn Parkinson’s Daily Activities Questionnaire-15: psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson’s disease. Park. Relat. Disord. 25, 21–26 (2016).
58. Kulisevsky, J. et al. Measuring functional impact of cognitive impairment: validation of the Parkinson’s disease cognitive functional rating scale. Park. Relat. Disord. 19, 812–817 (2013).
59. Geurtsen, G. J. et al. Parkinson’s disease mild cognitive impairment: application and validation of the criteria. J. Parkinson’s Dis. 4, 131–137 (2014).
60. Smith, P. J. et al. Aerobic exercise and neurocognitive performance: a meta-analytic review of randomized controlled trials. Psychosom. Med. 72, 239–252 (2010).
61. Lautenschlager, N. T. et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA 300, 1027–1037 (2008).
62. Sink, K. M. et al. Effect of a 24-month physical activity intervention vs health education on cognitive outcomes in sedentary older adults: The LIFE Randomized Trial. JAMA 314, 781–790 (2015).
63. Hindle, J. V., Petrelli, A., Clare, L. & Kalbe, E. Nonpharmacological enhancement of cognitive function in Parkinson’s disease: a systematic review. Mov. Disord. 28, 1034–1049 (2013).
64. Murray, D. K., Sacheli, M. A., Eng, J. J. & Stoessl, A. J. The effects of exercise on cognition in Parkinson’s disease: a systematic review. Transl. Neurodegener. 3, 5 (2014).
65. Goldman, J. G. & Weintraub, D. Advances in the treatment of cognitive impairment in Parkinson’s disease. Mov. Disord. 30, 1471–1489 (2015).
66. Reynolds, G. O., Otto, M. W., Ellis, T. D. & Cronin-Golomb, A. The therapeutic potential of exercise to improve mood, cognition, and sleep in Parkinson’s disease. Mov. Disord. 31, 23–38 (2016).
67. Petzinger, G. M. et al. Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson’s disease. Lancet Neurol. 12, 716–726 (2013).
68. Uc, E. Y. et al. Phase I/II Randomized Trial of aerobic exercise in Parkinson disease in a community setting. Neurology 83, 413–425 (2014).
69. Cruise, K. E. et al. Exercise and Parkinson’s: benefits for cognition and quality of life. Acta Neurol. Scand. 123, 13–19 (2011).
70. David, F. J. et al. Exercise improves cognition in Parkinson’s disease: the PRET-PD Randomized, Clinical Trial. Mov. Disord. 30, 1657–1663 (2015).
71. Tanaka, K. et al. Benefits of physical exercise on executive functions in older people with Parkinson’s disease. Brain Cogn. 69, 435–441 (2009).
72. McKee, K. E. & Hackney, M. E. The effects of adapted tango on spatial cognition and disease severity in Parkinson’s disease. J. Mot. Behav. 45, 519–529 (2013).
73. Park, D. C. et al. The impact of sustained engagement on cognitive function in older adults: the Synapse Project. Psychol. Sci. 25, 103–112 (2014).
74. Stine-Morrow, E. A., Parisi, J. M., Morrow, D. G. & Park, D. C. The effects of an engaged lifestyle on cognitive vitality: a field experiment. Psychol. Aging 23, 778–786 (2008).
75. Dobkin, R. D. et al. Neuropsychological outcomes after psychosocial intervention for depression in Parkinson’s disease. J. Neuropsychiatry Clin. Neurosci. 26, 57–63 (2014).
76. Fields, J. A. & Smith, G. E. Behavioral interventions to prevent or delay dementia. Natl. Acad. Neuropsychol. Bull. 28, 26–29 (2014).
77. National Academies of Sciences, Engineering, and Medicine 2017. Preventing Cognitive Decline and Dementia: A Way Forward. Washington, DC: The National Academies Press.
78. Leung, I. H. et al. Cognitive training in Parkinson disease: a systematic review and meta-analysis. Neurology 85, 1843–1851 (2015).
79. Institute of Medicine. Cognitive Aging: Progress in Understanding and Opportunities for Action (The National Academies Press, New York, 2015).
80. Edwards, J. D. et al. Randomized trial of cognitive speed of processing training in Parkinson disease. Neurology 81, 1284–1290 (2013).
81. Petrelli, A. et al. Effects of cognitive training in Parkinson’s disease: a randomized controlled trial. Park. Relat. Disord. 20, 1196–1202 (2014).
82. Cerasa, A. et al. Neurofunctional correlates of attention rehabilitation in Parkinson’s disease: an explorative study. Neurol. Sci. 35, 1173–1180 (2014).
83. Paris, A. P. et al. Blind randomized controlled study of the efficacy of cognitive training in Parkinson’s disease. Mov. Disord. 26, 1251–1258 (2011).
84. Pena, J. et al. Improving functional disability and cognition in Parkinson disease: randomized controlled trial. Neurology 83, 2167–2174 (2014).
85. Pompeu, J. E. et al. Effect of Nintendo Wii-based motor and cognitive training on activities of daily living in patients with Parkinson’s disease: a randomised clinical trial. Physiotherapy 98, 196–204 (2012).
86. Zimmermann, R. et al. Cognitive training in Parkinson disease: cognition-specific vs nonspecific computer training. Neurology 82, 1219–1226 (2014).
87. The Parkinson Alliance. Nutrition in Parkinson's Disease: A Closer Look from the Patient's Perspective. DBS4PD.org, USA, 2016.
88. Park, M. et al. Consumption of milk and calcium in midlife and the future risk of Parkinson disease. Neurology 64, 1047–1051 (2005).
89. Gao, X., O’Reilly, E. J., Schwarzschild, M. A. SpringerAmpamp; Ascherio, A. Prospective study of plasma urate and risk of Parkinson disease in men and women. Neurology 86, 520–526 (2016).
90. Seidl, S. E., Santiago, J. A., Bilyk, H. & Potashkin, J. A. The emerging role of nutrition in Parkinson’s disease. Front. Aging Neurosci. 6, 36 (2014).
91. Ross, G. W. et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 283, 2674–2679 (2000).
92. Devore, E. E., Kang, J. H., Breteler, M. M. & Grodstein, F. Dietary intakes of berries and flavonoids in relation to cognitive decline. Ann. Neurol. 72, 135–143 (2012).
93. Mastroiacovo, D. et al. Cocoa flavanol consumption improves cognitive function, blood pressure control, and metabolic profile in elderly subjects: the Cocoa, Cognition, and Aging (CoCoA) Study—a randomized controlled trial. Am. J. Clin. Nutr. 101, 538–548 (2015).
94. Nurk, E. et al. Intake of flavonoid-rich wine, tea, and chocolate by elderly men and women is associated with better cognitive test performance. J. Nutr. 139, 120–127 (2009).
95. Morris, M. C. et al. MIND diet slows cognitive decline with aging. Alzheimers Dement. 11, 1015–1022 (2015).
96. Tangney, C. C. et al. Adherence to a Mediterranean-type dietary pattern and cognitive decline in a community population. Am. J. Clin. Nutr. 93, 601–607 (2011).
97. Tangney, C. C. et al. Relation of DASH- and Mediterranean-like dietary patterns to cognitive decline in older persons. Neurology 83, 1410–1416 (2014).
98. Valls-Pedret, C. et al. Mediterranean diet and age-related cognitive decline: a randomized clinical trial. JAMA Intern. Med. 175, 1094–1103 (2015).
99. Smith, A. D. Prevention of dementia: a role for B vitamins? Nutr. Health 18, 225–226 (2006).
100. Durga, J. et al. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet 369, 208–216 (2007).
101. Morris, M. C. Nutrition and risk of dementia: overview and methodological issues. Ann. NY Acad. Sci. 1367, 31–37 (2016).
102. Xie, Y., Feng, H., Peng, S., Xiao, J. & Zhang, J. Association of plasma homocysteine, vitamin B12 and folate levels with cognitive function in Parkinson’s disease: a meta-analysis. Neurosci. Lett. 636, 190–195 (2017).
103. Annanmaki, T., Pessala-Driver, A., Hokkanen, L. & Murros, K. Uric acid associates with cognition in Parkinson’s disease. Park. Relat. Disord. 14, 576–578 (2008).
104. Peterson, A. L. et al. Memory, mood, and vitamin D in persons with Parkinson’s disease. J. Parkinson’s Dis. 3, 547–555 (2013).
105. Severson, M. A. et al. Patterns and predictors of institutionalization in community-based dementia patients. J. Am. Geriatr. Soc. 42, 181–185 (1994).
106. Cassidy, E. L., Baird, E. & Sheikh, J. I. Recruitment and retention of elderly patients in clinical trials: issues and strategies. Am. J. Geriatr. Psychiatry 9, 136–140 (2001).
107. Shah, K. et al. Sex differences in Parkinson’s disease caregiving (S48.003). Neurology 84, (2015).
108. Martinez-Martin, P. et al. Neuropsychiatric symptoms and caregiver’s burden in Parkinson’s disease. Park. Relat. Disord. 21, 629–634 (2015).
109. Schrag, A., Hovris, A., Morley, D., Quinn, N. & Jahanshahi, M. Caregiver-burden in Parkinson’s disease is closely associated with psychiatric symptoms, falls, and disability. Park. Relat. Disord. 12, 35–41 (2006).
110. Oguh, O., Kwasny, M., Carter, J., Stell, B. & Simuni, T. Caregiver strain in Parkinson’s disease: national Parkinson Foundation Quality Initiative Study. Park. Relat. Disord. 19, 975–979 (2013).
111. Schulz, R. & Beach, S. R. Caregiving as a risk factor for mortality: the Caregiver Health Effects Study. JAMA 282, 2215–2219 (1999).
112. Carter, J. H., Lyons, K. S., Stewart, B. J., Archbold, P. G. & Scobee, R. Does age make a difference in caregiver strain? Comparison of young versus older caregivers in early-stage Parkinson’s disease. Mov. Disord. 25, 724–730 (2010).
113. Lyons, K. S., Stewart, B. J., Archbold, P. G. & Carter, J. H. Optimism, pessimism, mutuality, and gender: predicting 10-year role strain in Parkinson’s disease spouses. Gerontologist 49, 378–387 (2009).
114. Grisso, T. & Appelbaum, P. S. Assessing Competence to Consent to Treatment: A Guide for Physicians and Other Health Professionals (Oxford Univ. Press, Oxford, 1998).
115. Karlawish, J. et al. Cognitive impairment and PD patients’ capacity to consent to research. Neurology 81, 801–807 (2013).
116. Moelter, S. T. et al. Research consent capacity varies with executive function and memory in Parkinson’s disease. Mov. Disord. 31, 414–417 (2016).
117. Abu Snineh, M., Camicioli, R. & Miyasaki, J. M. Decisional capacity for advanced care directives in Parkinson’s disease with cognitive concerns. Park. Relat. Disord. 39, 77–79 (2017).
118. Seppi, K. et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson’s disease. Mov. Disord. 26(Suppl. 3), S42–S80 (2011).
119. Dubois, B. et al. Donepezil in Parkinson’s disease dementia: a randomized, double-blind efficacy and safety study. Mov. Disord. 27, 1230–1238 (2012).
120. Petersen, R. C. et al. Practice guideline update summary: mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 90, 126–135 (2018).
121. Liu, G. et al. Prediction of cognition in Parkinson’s disease with a clinical–genetic score: a longitudinal analysis of nine cohorts. Lancet Neurol. 16, 620–629 (2017).
122. Eberling, J. et al. Therapeutic development paths for cognitive impairment in Parkinson’s disease: report of a regulatory roundtable. J. Parkinson’s Dis. 4, 585–589 (2014).